English
Spanish
French
Italian
German
NEWS
Latest News
Guidelines Are a First Step. The Harder Work Comes Next.
Today
HSF President Dr. Haley Naik reflects on nearly two decades treating hidradenitis suppurativa, from a time with no approved therapies to today's landscape of three FDA-approved options and a growing pipeline. In a new op-ed, she previews the upcoming joint AAD/HSF clinical management guidelines, why timely systemic treatment matters, and the three priorities that will determine whether this milestone actually changes patients' lives: access, research, and maintenance.
Read more
GLP-1 Receptor Agonist Use and Clinical Outcomes in Patients With Hidradenitis Suppurativa
September 19, 2026
New research just published in JAMA Dermatology: in a study of over 40,000 people with HS, those taking GLP-1 medications (like semaglutide and tirzepatide) saw significantly lower rates of death, cardiovascular events, and serious infections compared to those who weren't. 📚 More research is needed to understand why, but it's a promising sign for whole-body care in HS. Read the full study for more information.
Read more
Biologic Therapy in Pediatric Hidradenitis Suppurativa: New Approvals, New Questions
September 8, 2026
Nearly half of people with hidradenitis suppurativa report symptoms starting in childhood, yet treatment options for young patients have long lagged behind those for adults. A new article from The Dermatologist explores how two recently approved biologics, adalimumab and secukinumab, are changing that picture, and why treating early may help prevent the scarring that comes with delayed care. Read the full piece to learn what this means for adolescents with HS and their families.
Read more
Ultrasound as a Transformative Tool in Dermatology
September 3, 2026
Could ultrasound be the key to faster HS diagnosis? Dermatologists are using high-frequency imaging to spot subclinical tunnels and inflammation invisible to the naked eye, potentially cutting years off the diagnostic delay HS patients face. Read how this "fourth eye" is changing the way clinicians see and treat HS.
Read more
There Was No Playbook for HS Care. There Is One Now.
August 25, 2026
"HS is becoming a disease the community can treat, not something only specialty clinics know how to manage." Three newly approved therapies, a pipeline of oral and biologic options, and updated clinical guidelines with a live-update process are reshaping how HS gets treated, and why medication and surgery now work best together, not as either/or options. Read the full piece to see what's changed.
Read more
HS Immunopathogenesis Drives Expansion of Targeted Therapeutic Strategies
August 21, 2026
At Music City SCALE 2026, Dr. James Krueger outlined how new insights into HS's immune drivers, from neutrophil-heavy inflammation to a surprisingly strong B-cell and plasma cell signature, are reshaping the treatment pipeline. He pointed to CXCL13 and Bruton's tyrosine kinase as emerging targets alongside the more established IL-17, TNF, OX40L, and IL-1 pathways. The result is a fast-expanding pipeline, including JAK1 inhibitors for patients who fail TNF inhibitors, bispecific antibodies, and novel nanobody-based treatments, aimed at matching therapy to HS's diverse immune profile.
Read more
Can Supplements Help to Address Acne? With Steven Daveluy, MD
August 14, 2026
Whey protein might be sabotaging your patients' acne treatment, and they have no idea. 🥛 Steven Daveluy, MD breaks down the surprising dairy-acne connection and why probiotics only work when the strain actually matches the condition.
Read more
Why Povorcitinib's JAK1 Mechanism Matters for HS Treatment
August 9, 2026
In a new HCPLive interview, Dr. Martina Porter explains why HS has lagged behind conditions like psoriasis in effective treatment options, and what povorcitinib's arrival could change. As a selective JAK1 inhibitor, it avoids the JAK2/JAK3 pathways linked to hematopoietic side effects, and its oral, needle-free format may appeal to patients hesitant about injections. Because JAK1 inhibition works through a broader pathway than TNF-alpha or IL-17 inhibition, Porter suggests it could offer an alternative for patients who haven't responded to existing biologics, particularly those with early nodular or severe tunneling disease.
Read more
Topical Ruxolitinib Shows Promise for Early-Stage Hidradenitis Suppurativa
July 27, 2026
New Phase 2 data suggest that topical ruxolitinib cream may help address a major unmet need in mild-to-moderate hidradenitis suppurativa. Patients treated with the JAK1/2 inhibitor experienced significant reductions in inflammatory lesions, high clinical response rates, and a favorable safety profile, highlighting its potential as a targeted therapy for early-stage disease.
Read more
The First Doctor an HS Patient Sees Is Usually Not a Dermatologist
July 22, 2026
Most people with hidradenitis suppurativa don't meet a dermatologist first. They meet primary care, OB/GYN, urgent care, or the ER, and that's usually where the 7 to 10 year delay to diagnosis begins. Dr. Steven Daveluy, who has spent over a decade teaching non-dermatology clinicians about HS, breaks down the single question that can catch the disease early, what frontline providers can do while patients wait to see a specialist, and why the upcoming AAD/HSF guidelines could change the financial and clinical case for treatments like laser hair removal.
Read more